NCT02112656Phase 3Completed

Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)

Study sponsor: Imunon

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2020-04-27Actual

Enrollment · participants554Actual

Source updated2024-08-20Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Hepatocellular Carcinoma

Treatments or interventions studied

ThermoDoxDrugAlso known as Lyso-Thermosensitive Liposomal Doxorubicin (LTLD)
Dummy infusionDrugAlso known as Placebo

Primary outcomes · main study measures

measure: Overall Survival (OS); description: Overall survival is defined as the time (in months) from the date of randomization to the death from any cause or the end of the study.; timeFrame: All subjects to be contacted every 3 months after radiological progression for vital status reporting. Subjects were followed for OS up to 68 months from randomization.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history